For research use only. Not for therapeutic Use.
Etofylline clofibrate has ypolipidemic and antithrombotic effect. Etofylline clofibrate has an agonistic interaction with intimal PGI2[1].
Etofylline clofibrate (p.o.; 12 mg/kg) has the moderate effect of a single dose (12% reduction in disaggregation time) and has a maximum reduction of 31 and 43% following 5 and 7 consecutive daily applications, respectively[1].
| Catalog Number | I009467 |
| CAS Number | 54504-70-0 |
| Synonyms | 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)ethyl 2-(4-chlorophenoxy)-2-methylpropanoate |
| Molecular Formula | C19H21ClN4O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H21ClN4O5/c1-19(2,29-13-7-5-12(20)6-8-13)17(26)28-10-9-24-11-21-15-14(24)16(25)23(4)18(27)22(15)3/h5-8,11H,9-10H2,1-4H3 |
| InChIKey | KYAKGJDISSNVPZ-UHFFFAOYSA-N |
| SMILES | CC(C)(C(=O)OCCN1C=NC2=C1C(=O)N(C(=O)N2C)C)OC3=CC=C(C=C3)Cl |
| Reference | [1]. Metz G, et al. Effect of etofylline clofibrate on experimental thrombus formation and prostacyclin activation. Arzneimittelforschung. 1986 Sep;36(9):1363-5. |
